Clinical trial
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
NCT00412061 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00412061 |
|---|---|
| Title | Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor |
| Official title | A Randomized, Double-blind Placebo-controlled, Multicenter Phase III Study in Patients With Advanced Carcinoid Tumor Receiving Octreotide Depot and Everolimus 10 mg/Day or Octreotide Depot and Placebo |
| Acronym | RADIANT-2 |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoid Tumor, Malignant Carcinoid Syndrome |
| Intervention type | Drug |
| Interventions | Octreotide, Placebo, Everolimus |
| Enrollment | 429 |
| Start date | Dec 1, 2006 |
| Primary completion | Apr 1, 2010 |
| Completion | Jun 1, 2013 |
| First posted | Dec 15, 2006 |
| Last update posted | Nov 21, 2014 |
| Countries | Australia, Belgium, Canada, Czechia, Finland, France, Germany, Greece, Italy, Netherlands, Slovakia, Spain and 3 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: